Price movement over the last 24 hours
AbbVie Inc vs Build A Bear Workshop Inc — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Build A Bear Workshop Inc trades at $30.09 (market cap $388.91M). The key difference: AbbVie Inc is far larger — about 1156.8× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| ABBV | BBW | |
|---|---|---|
Market Cap | $449.91B | $388.91M |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $75.85 |
52-Week Low | $184.85 | $29.84 |
Enterprise Value | $513.38B | $488.35M |
Dividend Yield | 2.72% | 2.97% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Build-A-Bear Workshop (BBW) trades at $31.02, down 1.52% on the day, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics, including a P/E of 7.26 and a P/S of 0.76, alongside strong profitability with a net income margin of 10.48%. Recent developments include a CEO transition to Chris Hurt and the declaration of a $0.23 quarterly dividend payable in July 2026.
The long-term outlook is supported by a debt-free balance sheet, international expansion, and a 72.73% analyst buy rating with a $62.50 consensus price target, implying significant upside. Near-term risks include consumer spending pressures and revenue guidance reductions, but the fundamental setup remains attractive for recovery in the latter half of the year.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →